Search results
Showing 661 to 675 of 2581 results for methods
NICE's partners
What NICE does Our guidance About technology appraisal guidance Our methods and processes (health technology evaluation manual)...
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
NICE has developed a medtech innovation briefing (MIB) on moorLDLS-BI for burn depth assessment .
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Awaiting development Reference number: GID-TA11565 Expected publication date: 21 May 2026
In development Reference number: GID-TA11576 Expected publication date: 18 June 2026
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]
In development Reference number: GID-TA11643 Expected publication date: 18 March 2026
Consultation on changes to technology appraisals and highly specialised technologies
About technology appraisal guidance Our methods and processes (health technology evaluation manual) Methods and processes...
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Awaiting development Reference number: GID-TA11018 Expected publication date: TBC
In development Reference number: GID-TA11772 Expected publication date: 03 September 2026
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]
In development Reference number: GID-TA10024 Expected publication date: 28 June 2017
This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.
This guideline covers planning and delivering multi-agency services for domestic violence and abuse. It aims to help identify, prevent and reduce domestic violence and abuse among women and men in heterosexual or same-sex relationships, and among young people.
Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]
In development Reference number: GID-TA11473 Expected publication date: TBC
Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]
In development Reference number: GID-TA11553 Expected publication date: TBC